Introduction: Heart failure (HF) is understudied among women; especially, genomic evidence implicating shared or unique mechanisms of HF with respect to reduced or preserved ejection fraction (HFrEF, HFpEF) is lacking across ethnic populations of women.
Introduction 1
According to the American Heart Association (AHA), approximately 6.5 million U.S. 2 adults have heart failure (HF) in 2018 1 , representing a major cause of morbidity and mortality 3 in the United States. Heart failure is phenotypically and genetically heterogeneous, and much 4 remains unknown about the etiology for subtypes of HF, including HF with preserved 5 ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF). Of note as many 6 as 40-71% of patients have HFpEF for which limited clinical treatment options are available 7 with little to no impact on outcomes 2 . Moreover, HF is understudied in women, who 8 experience a higher mortality than men 1 . African American (AA) women have the highest 9 HF incidence, followed by Hispanic Americans (HA) and European Americans (EA), and 10 morbidity and mortality are twice as high for AA women relative to EA [3] [4] [5] [6] . Observational 11 studies have shown that while patients with HFpEF and HFrEF often display similar clinical 12 symptoms, they often have markedly different risk factors, underlying pathophysiological 13 processes, and responses to clinical therapies 7 . Many therapies with unequivocal benefit in 14
HFrEF have failed to show efficacy for HFpEF 8, 9 . Thus, there is a urgent need to further 15 research biological pathways and gene networks for HFpEF and HFrEF that could provide 16 mechanistic insight into the disease processes and identify potential targets for novel 17 treatment modalities, particularly for women, who are disproportionately affected by HF 1 . 18 Recent candidate gene studies and genome-wide association studies (GWAS) have 19 identified several genetic loci (such as ADRB1, USP3, ITPK1, and BAG3 genes 10,11 20 associated with HF risk. However, these studies are primarily focused on genes associated 21 with inherited HFrEF and are limited by reproducibility, effect size, and lack of ethnic 22 diversity 10, 11 . Although women are at higher risk of HF, no studies to date have 23 examined/observed sex-specific genetic variants. Moreover, few studies have directly 24 investigated the genetic mechanisms underlying the two HF subtypes, HFpEF and 25 HFrEF 12, 13 ; and no studies were conducted in an ethnically diverse population of women. As 26 genes tend to behave conjointly on HF processes, analyzing a cluster of genes with related 27 biological functions, using an integrative pathway and network approach 14, 15 , improves the 28 statistical power to identify genetic variants of biological importance. To enhance the 29 understanding of biological mechanisms underlying different HF phenotypes (HFpEF versus 30 HFrEF) as well as genomic and ethnic diversity in women with HF, we therefore investigated 31 genetic risk factors and biological pathways predisposing to HF and its subtypes among AA 32 and EA women in the Women's Health Initiative (WHI) study. We replicated our findings 33 using AA women from the JHS, EA from FHS, and HA women from the WHI. 34 
35
Methods 36
Study Population 37
Discovery Population 38
The WHI study enrolled 161,808 postmenopausal women aged between 50 and 79 39 years old from 1993 to 1998. The original WHI study has two major components: a partial 40 factorial randomized clinical trial (CT) including 68,132 participants and an observational 41 study (OS) of 93,676 participants. The detailed study design has been reported elsewhere 16 . 42 Briefly, medical records from enrollment through September 2014 for 44, 174 WHI 43 participants, including all women randomized to the hormone trial component (n = 27,347) 44 and all AA participants (n = 11,880) and HA participants (n = 4,947) from the CT and the 45 OS, were sent to the University of North Carolina (UNC) for HF adjudications. 46
Of the participants enrolled in the WHI-OS, 8,515 self-identified AA women had 47 consented to and were eligible for the WHI-SNP Health Association Resource (SHARe), and 48 of the participants enrolled in the WHI hormone trial, 4,909 EA women were included in the 49 WHI-Genomics and Randomized Trials Network (GARNET). After quality control, the 50 standard GWAS and pathway analyses were conducted among 8,298 AA and 4,257 EA 51 participants of the WHI. Considering the lack of replication cohort of HA participants in the 52 WHI-SHARe, we treated the HA participants as a replication sample in the pathway analysis. 53
54

Population for validation and replication 55
The current study included three populations as validation and replication: AA in the 56 
Genome-wide association analyses 89
We performed standard GWAS analysis for HFrEF and HFpEF for AA and EA 90 women, using multivariable logistic regressions. The regression models were implemented 91 using allelic dosage at each SNP (single-nucleotide polymorphism) as the independent 92 variable, with covariate adjustment for age, age 2 , and first four principal components (PCs) 93 for global ancestry in all three cohorts. We also adjusted for region in two WHI cohorts, and 94 randomized hormone treatment group and baseline hysterectomy status in the WHI-95 GARNET study. Since the associations between germline genetic variants and HF are not 96 confounded by demographic and lifestyle factors, no other confounders were adjusted in the 97 GWAS analysis. The general form of the GWAS model is specified as follows: 98
where Y denotes HF subtype, G denotes SNPs, and V denotes adjusted covariates. Common 100 genetic variants reaching the suggestive significance (5 ൈ 1 0 ି ) were identified as potential 101 GWAS hits. Suggestive SNPs were validated in the JHS and FHS using nominal P value < 102 0.05, followed by cross-ethnicity meta-analyses combining AA, EA, and HA women from 103 WHI, JHS, and FHS using METAL 19 (FDR-adjusted q value < 0.05). 104 105
Pathway analysis 106
We obtained knowledge-driven metabolic and signaling pathways from three 107 databases: the Kyoto Encyclopedia of Genes and Genomes (KEGG) 20 , Reactome 21 , and 108 BioCarta 22 . SNPs showing potential associations with HF subtypes (P value <0.05 in GWAS) 109 were mapped to relevant genes based on their chromosome locations or functions, and further 110 mapped to biological pathways. Each pathway was tested for enrichment of genetic signals 111 for HFrEF and HFpEF by ethnic groups. To avoid potential biases due to a particular method, 112 we applied two different well-established methods based on known biological pathways: 1) 113 GSA-SNP 14 , and 2) Mergeomics 15 . Pathways were defined as significant if they met the 114 following criteria: 1) identified by both methods from the WHI study with a FDR-adjusted q 115 value < 0.2; and 2) validated by GSA-SNP or Mergeomics with a significant P value after 116
Bonferroni correction in JHS (as replication of WHI-AA) and FHS (as replication of WHI-117 EA). We then performed cross-phenotype and cross-ethnicity analyses in WHI to examine 118 shared pathways between HFrEF and HFpEF, as well as phenotype-specific pathways, across 119 ethnicities (AA, EA, and HA). 120 121
Key Driver Analysis for Identification of Key Regulatory Genes for HF-related Pathways 122
As hundreds of genes are involved in the biological pathways, we seek to further 123 prioritize key driver (KD) genes, defined as genes that played a central role in the disease 124 progress and once perturbed, should have major impact on many other genes. We integrated 125 all genes involved in significant pathways with seven Bayesian networks and one protein-126 protein interaction network using KD analysis methods 15, 23, 24 . We designed a normalized 127 rank score (NRS) to summarize the consistency and strength of identified KD genes across 128 multiple networks 25 
is the count of networks from 129 which a KD was identified; Table 1 . Compared 146 to WHI-EA, WHI-AA women were younger in age and less physically active, had higher 147 BMI and lower intakes of alcohol and total calories, and with a higher proportion of 148 cardiovascular disease and diabetes.
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Identification of Significant Genetic Loci Using Standard GWAS Analysis 151
In the validation analysis of previously reported 30 loci for HF from the GWAS 152 catalog 26 , we validated one locus and further allocated it to HFpEF in the WHI, JHS, and 153 FHS populations with FDR-adjusted q value < 0.05. The validated SNP rs4420638 is located 154 on chromosome 19 and close to APOE and APOC genes. Detailed information regarding the 155 validated locus can be found in Supplemental Table 1 . 156
The standard GWAS results for HFrEF and HFpEF within WHI-AA (n=7,982) and 157 WHI-EA (n=4,133) are shown in the Manhattan plots ( Supplementary Figure 1) . Among 158 AA, this discovery analysis revealed one significant (P < 5×10 -8 , rs35900865) and 57 159 suggestive (P < 5×10 -6 ) SNPs related to HFrEF, and three significant (P < 5×10 -8 , rs7834398, 160 rs78668964, and rs12203350) and 94 suggestive (P < 5×10 -6 ) SNPs related to HFpEF. 161
Among EA, we failed to identify significant SNPs, but found 50 suggestive (P < 5×10 -6 ) 162
SNPs related to HFrEF and 47 SNPs for HFpEF. 163
In the replication analysis for AA women among JHS (n=1,853) participants, eight 164 SNPs from four loci (lead SNPs: rs12067046, rs114553497, rs10229703, and rs149663839) 165 out of 94 SNPs for HFpEF reached the threshold of P < 0.05. In the replication analysis for 166 EA women among FHS (n=1,755) participants, one SNP (rs12719020) reached the P < 0.05 167 threshold among the 50 suggestive SNPs for HFrEF; and 19 SNPs (concentrated on 168 chromosome 16, lead SNP: rs12599260) among the suggestive 47 SNPs for HFpEF reached 169 the threshold of P < 0.05. The effect of all lead SNPs on HF was in the same direction in the 170 discovery population and the ethnicity-specific replication population. In the cross-ethnicity 171 meta-analysis combining AA, EA, and HA women from the WHI, JHS and FHS, all loci 172 passed ethnicity-specific validation and were further validated with FDR-adjust q value of < 1 1 0.05 ( Table 2) . More information regarding the newly discovered loci can be found in 174 Supplemental Table 1 . 175 176 Identification of Biological Pathways Using Integrative Pathway Analysis 177
We initially identified 21 pathways for HFrEF (nine for EA and 12 for AA) and 42 178 pathways for HFpEF (31 for EA and 17 for AA) among WHI participants, of which 11 179 pathways were validated for HFrEF and 15 pathways for HFpEF, among the JHS and FHS 180 women. The results of cross-phenotype and cross-ethnicity analysis were presented in Table  181 3 and Supplemental Tables 2 and 3 . Based on the functions of the pathways, we identified 182 two main overarching domains with some cell signaling and metabolism common to both: 1) 183 angiogenesis and vascular patterning and 2) inflammation. Five pathways, emerging from 184 angiogenesis and vascular patterning, were shared between HFrEF and HFpEF across AA, 185 EA, and HA women, namely, extracellular matrix (ECM)-receptor interaction, cell adhesion 186 molecules (CAMs), axon guidance, netrin-1 signaling, and developmental biology ( Figure  187 1). The five shared pathways were highly interconnected as demonstrated by a shared 188 common set of 256 genes among them (Figure 2) . 189
In addition, we found six pathways specifically enriched for HFpEF across AA and 190 EA, namely, adherens junction, endocytosis, phosphatidylinositol signal system, vascular 191 smooth muscle contraction, and heparan sulfate/heparin (HS)-glycosaminoglycan (GAG) 192 biosynthesis and degradation; all of which corresponded to the domain of angiogenesis and 193 vascular patterning (Figures 1 and 3) . Of the aforementioned six HFpEF-specific pathways, 194 the first three pathways were further replicated in the WHI-HA participants. 195 196
Identification of Key Drivers for HFpEF and HFrEF 197
In the KD analysis to identify potential genes that played a central role in the 198 significant pathways for HF, we used eight different regulatory or interaction networks that 199 capture gene-gene or protein-protein interactions among the pathways. The In this GWAS analysis of 7,982 AA and 4,133 EA women from the WHI, we 213 validated one previously reported genetic locus and allocated it to HFpEF, and additionally 214 discovered one HFrEF and five HFpEF novel genetic loci of potential importance. Also, five 215 biological pathways appeared to be shared for both HFrEF and HFpEF across AA, EA, and 216 HA women, and six pathways were specific for HFpEF across AA and EA women. Our 217 results suggested the presence of core mechanisms across HF subtypes (HFrEF and HFpEF), 218 such as vascular remodeling and inflammation alone with some common overlapping 219 mechanisms of cell signaling and metabolism. It is important to note the paucity of 220 cardiomyocyte-specific gene variants, including those for nuclear envelope proteins, 221 sarcomere proteins, cytoskeletal, and calcium regulatory proteins, given their extensive 222 involvement in familial dilated cardiomyopathies. Our data highlight the genetic and/or 223 biological significance of the vascular remodeling and inflammation, rather than that of the 224 cardiomyocyte in the acquisition of HFpEF and HFrEF. 225
Given the increased diversity of gene involvement, the genetic architecture underlying 226
HFrEF and HFpEF remains challenging to delineate. We validated one previously reported 227 locus close to APOE and APOC, and further allocated it to HFpEF. Genes in the 228 apolipoprotein family (APOE, APOC1, APOC2, etc.) encode lipid transport proteins that 229 regulate cholesterol metabolism and are associated with obesity and cardiovascular 230 disease 27, 28 . Of note, we were not able to validate other suggestive HF loci reported from 231 previous European-based cohorts, which may be due to effect modifications by sex and/or 232 ethnicity. 233
In addition, we discovered one HFrEF and five HFpEF loci from intergenic regions. 234
Variant rs12719020, associated with HFrEF, is located upstream (< 20 Kb) to COBL, a gene 235 related to vasculitis and type 1 diabetes 29 . For variants associated with HFpEF, rs12067046 is 236 located 500 Kb downstream of PLXNA2, which is related to the development of blood 237 vessel 30 and inflammatory-induced immune disorders 31 ; the linkage disequilibrium (LD) 238 block around rs12599260 is upstream (5 Kb) to HEATR3, which regulates inflammatory 239 immune response 32 ; rs149663839 is located upstream (50 Kb) to CAT, a key antioxidant 240 enzyme, which is hypothesized to play a role in the development of many chronic or late-241 onset diseases such as HF 33 ; ACTA1 (60 Kb to the LD block around rs114553497) and 242 CALD1 (5 Kb to rs10229703) are fundamental genes for skeletal/smooth muscle contraction 243 and had been linked to pulmonary hypertension in animal studies 34, 35 ( Table 2 37 , and LV function 38 . Our 248 pathway-based analysis revealed five consistent pathways between HFrEF and HFpEF across 249 the two ethnicities ( Table 3) . All the five pathways were linked to angiogenesis and vascular 250 patterning, among which three pathways, ECM-receptor interaction, CAMs, and Netrin-1 251 signaling were also linked to inflammation (Figure 1) . From the five pathways shared by 252 both HFrEF and HFpEF, three pathways, axon guidance, ECM-receptor interaction, and 253
CAMs, had been implicated previously in thromboembolic cardiovascular disease, type 2 254 diabetes, and LV function 25, 38 . 255
There appears to be a substantial overlap in the major areas of inflammation and 256 angiogenesis among shared pathways between HFrEF and HFpEF. The ECM is an intricate 257 network composed of multidomain macromolecules organized to support mechanical and 258 structural properties of cells and tissue but also to control behavioral characteristics of cells, 259 including proliferation, adhesion, migration, polarity and differentiation 39, 40 following an insult has potential to drive the progression toward HF, including myocardial 277 fibrosis and altered ECM protein orientation 46, 47 . Details regarding the main functions of 278 other identified pathways can be found in Supplemental Table 4 . 279
Taken together, the above identified pathways highlight the previously known but 280 likely underappreciated importance of angiogenesis and vascular patterning as well as 281 inflammation on HF that appear to link HFrEF and HFpEF to other cardio-metabolic health 282 outcomes via multiple mechanisms. The fact that these pathways were consistently identified 283 across multiple ethnicities further highlights a convergent or central role in the joint 284 mechanisms between interrelated cardiac diseases. 285
We additionally identified six pathways specifically for HFpEF across ethnicities. All 286 the six pathways were linked to angiogenesis and vascular patterning, from which three 287 pathways (phosphatidylinositol signal system, HS-GAG biosynthesis and degradation) were 288 additionally linked to inflammation (Figure 1) . None of the six HFpEF pathways have 289 previously been implicated in pathway-based studies, making these findings novel. 290
Specifically, the phosphatidylinositol signaling system is critically linked to 291 inflammation and vascular remodeling, and in particular angiogenesis and vascular 292 patterning. Activation of the PI3K pathway can occur in response to a variety of extracellular 293 (e.g., ECM, CAM) as well as growth factor (e.g., fibroblast growth factor, VEGF-A) 294 signaling and can regulate broad spectrum of molecular functions which involve 295 proliferation, adhesion, migration, invasion, metabolism and cell survival 48, 49 . Activation of 296 the PI3K pathway involves recruitment via Src-homology 2 (SH2) to phosphotyrosine 297 residues on the intracellular portion of membrane receptors, followed by phosphorylation of 298 phosphatidylinositol-4,5-bisphosphate (PIP2) to generate the second messenger molecule 299 PIP3. The Akt family of serine/threonine kinases has been shown to be the primary 300 downstream mediator of the effects of PI3K. Through the phosphorylation of IκB kinase 301 (IKK) and activation of nuclear factor κ B (NF-κB) transcriptional activity, Akt leads to 302 upregulation of inflammatory and prosurvival genes [50] [51] [52] [53] . Akt can also activate mTOR, 303 resulting in stabilization of hypoxia inducible factor-1 (HIF-1) and consequent expression of 304 VEGF-A in order to promote angiogenesis [54] [55] [56] . PI3K signaling may also play a role in 305 regulating cardiomyocyte size, survival, and inflammation during cardiac hypertrophy and 306 HF, in part via calcium signaling 57, 58 . Details regarding the main functions of other identified 307 pathways can be found in Supplemental Table 4 . Detailed knowledge of these relationships 308 at the molecular level will allow researcher to understand the distinct mechanisms underlying 309
HFpEF and enable the development of effective therapeutic strategies. 310
In addition, we observed two pathways with highly significant P values: Rac1 311 pathway for HFrEF within EA and HFpEF within AA, and signaling by bone morphogenetic 312 proteins (BMP) pathway for HFpEF among AA (Supplemental Tables 2, 3, and 4) . Rac1 is 313 a GTPase protein, a member of the Rac subfamily of the Rho family of GTPases, and plays a 314 critical role in inflammation and vascular remodeling. Activated Rac1 can promote NF-κB 315 signaling and reactive oxygen species (ROS) production via nicotinamide adenine 316 dinucleotide phosphate (NADPH) oxidase, both known activators of the NACHT, LRR, and 317 PYD domains-containing protein 3 (NLRP3) inflammasome protein complex that promotes 318 expression of the critical inflammatory cytokine, interleukin-1β (IL-1β) [59] [60] [61] . A number of 319 studies have found that activation of Rac1 is associated with atrial fibrillation 62 , 320 atherosclerotic calcification 63 , cardiac hypertrophy 64 , and HF 65 , suggesting Rac1 may have 321 strong potential as a new therapeutic target 66 . BMPs belong to transforming growth factor 322 beta (TGFβ) superfamily, which is one of the most potent profibrogenic cytokine systems 323 governing cardiac fibrosis 67 . BMP signaling is also increasingly recognized for its influence 324 on endocrine-like functions in postnatal cardiovascular and metabolic homeostasis 68 . Some 325 BMP molecules, such as BMP9 and BMP10, had been found to reduce pulmonary arterial 326 hypertension, cardiac fibrosis, and myocardial infarction, thereby providing potentially 327 benefits for HF patients 68, 69 . 328
The KD gene analysis prioritized KD genes of coronary heart disease 70 , type 2 329 diabetes 25 , and obesity 71 , but has not been performed for HF. In our KD gene analysis based 330 on shared pathways between HFrEF and HFpEF, we found that the KD genes belong to the 331 collagen gene family, shared between axon guidance and ECM-receptor interaction, and 332 HLA genes from CAMs pathway. HLA gene family members are components of the major 333 histocompatibility complex (MHC) and play a central role in the immune system with 334 established allelic contributions to type 1 diabetes susceptibility 72 , and a host of inflammatory 335 disorders, including rheumatoid arthritis 73 , Sjögren's 74 , ulcerative colitis 75 , and systemic 336 lupus erythematosus 76 . Collagen gene family, as previously described, encodes proteins to 337 regulate vascular patterning and maintain the structure and function of cardiomyocytes. 338
These KD genes further highlight the effect of angiogenesis, vascular patterning and 339 inflammation in HF. Importantly, genes COL1A1 and COL3A1 were also found to be the KD 340 genes for thromboembolic cardiovascular disease and type 2 diabetes 25 ; thus, showing 341 potential shared biological mechanisms underlying these interrelated diseases as well as the 342 pleiotropic effects of these KD genes. COL4A2 is a critical component of the basement 343 membrane, and loss of function leads to disordered capillary networks during 344 angiogenesis 77, 78 . The C-terminal portion of COL4A2 is a potent inhibitor of angiogenesis, 345 prevents proliferation and migration of endothelial cells and induces apoptosis 79 . Moreover, 346 variants of COL4A2 are implicated in vascular cell survival, atherosclerotic plaque stability 347 and risk of myocardial infarction, as well as hemorrhagic stroke 80, 81 . 348
The KD genes for HFpEF were mainly from the vascular smooth muscle contraction, 349 arterial and aortic aneurysmal disease 84,85 . 357 Several strengths and limitations need to be considered when interpreting these 358 findings. First, this study represents the first attempt to systematically examine and integrate 359 genetic variants for HF phenotypic subtypes using pathway and network approaches with 360 special emphasis on revealing mechanistic similarities and differences between HFrEF and 361 HFpEF with higher statistical efficiency. The second strength is the large, previously 362 validated and high-quality phenotyping of women of different ethnic backgrounds, which 363 allows the detection of HF mechanisms shared across ethnicities. Thirdly, two additional 364 high-quality cohorts, JHS and FHS, served as replication populations supporting the 365 robustness of our findings. One major limitation is that our results were based upon germline 366 mutations. Therefore, it is unclear whether mutations in the identified genomic regions and 367 pathways would impact downstream expression levels in particular tissues of interest, and 368 whether the identified genes and pathways are up-/down-regulated before and after HF 369 events. This highlights the critical need for future studies that will quantify the downstream 370 gene expression changes by comparing population with and without HF. Moreover, it will be 371 important to validate these results in men in order to examine the effect of sex on HF and to 372 replicate our finding using suitable animal models of HF in order to further validate these 373 newly discovered pathways. 374 375
Conclusion 376
This study validated previously identified locus and defined novel loci for HF and its 377 subtypes, implicating specific molecular pathways, some shared and others unique, that 378 contribute to HF and its subtypes. We highlight the significant mechanistic role of the 379 Extracellular matrix-receptor interaction X X X X X X Cell adhesion molecules X X X X X X Netrin-1 signaling X X X X X X Phosphatidylinositol signal system X X X HS-GAG biosynthesis X X X HS-GAG degradation X X Rac1 pathway X X NRAGE signals death through JNK X X Signaling by Rho GTPases X X X X Cell-cell junction organization X X Intrinsic pathway X X X 
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